Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ONCY | US
-0.01
-0.94%
Healthcare
Biotechnology
30/06/2024
05/03/2026
1.05
1.06
1.08
1.03
Oncolytics Biotech Inc. a development-stage biopharmaceutical company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep an intravenously delivered immunotherapeutic agent which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary Canada.
View LessPrice Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
88.2%1 month
125.2%3 months
103.0%6 months
89.6%-
-
7.80
-
-
-1.79
-
-
-36.45M
80.70M
80.70M
-
-
-
-
-138.22
5.43
1.41
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.23
Range1M
0.40
Range3M
0.51
Rel. volume
0.54
Price X volume
1.05M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CRDF | CRDF | Biotechnology | 1.87 | 87.05M | -5.56% | n/a | 3.52% |
| Aptevo Therapeutics Inc | APVO | Biotechnology | 6.46 | 86.83M | -4.01% | n/a | 112.59% |
| Fortress Biotech Inc | FBIO | Biotechnology | 3.13 | 86.27M | 0.97% | n/a | 494.61% |
| Milestone Pharmaceuticals Inc | MIST | Biotechnology | 1.59 | 84.70M | -3.64% | n/a | 166.53% |
| LYRA THERAPEUTICS INC | LYRA | Biotechnology | 1.29 | 84.44M | 2.38% | n/a | 118.63% |
| Tenaya Therapeutics Inc. Common Stock | TNYA | Biotechnology | 0.8193 | 83.69M | 40.92% | n/a | 11.62% |
| Pyxis Oncology Inc. Common Stock | PYXS | Biotechnology | 1.35 | 80.22M | -9.40% | n/a | 12.29% |
| PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.53 | 78.83M | 2.00% | n/a | 6.06% |
| Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.3769 | 78.48M | -4.63% | n/a | 122.82% |
| Pliant Therapeutics Inc. | PLRX | Biotechnology | 1.29 | 78.43M | 0.00% | n/a | 15.34% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.43 | 71.57M | -1.12% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 2.32 | 41.90M | 0.87% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.29 | 33.46M | -2.04% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.71 | 13.72M | 23.48% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.9 | 5.94M | -2.99% | n/a | 204.46% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.404 | 3.85M | -1.46% | n/a | 19.98% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | -4.95% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 1.36M | 0.00% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0071 | 654.72K | 0.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.79 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.80 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 102.99 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 80.70M | 3.66B | Emerging |